1.   

On 26 October 2018, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).

This notification concerns the following undertakings:

—	CVC Capital Partners SICAVFIS SA (‘CVC’) (Luxembourg), and

—	Recordati SpA (‘Recordati’) (Italy).

CVC acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Recordati.

The concentration is accomplished by way of purchase of shares.

2.   

The business activities of the undertakings concerned are:

—   for CVC: management of investment funds and platforms. Portfolio companies controlled by CVC notably include companies active in the pharmaceutical sector: Alvogen, DOC Generici, and Theramex,

—   for Recordati: development and manufacturing of pharmaceutical products.

3.   

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4.   

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.9044 — CVC/Recordati

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

E-mail: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË